Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Up 9.7% in May, Pushed by 2 Extra Working Days: Crecon Report
July 9, 2012
- MTPC Launches Argatroban for HIT Type II in the UK
July 9, 2012
- Bayer Confident in Pipeline, Regards Japan as Strategically Important Country: Mr Fibig
July 6, 2012
- Takeda Completes Acquisition of Multilab, Mid-Sized Brazilian Pharm Company
July 5, 2012
- Zonegran Approved for Monotherapy in Europe: Eisai
July 5, 2012
- Nippon Kayaku Considers Promotional Measures for Biosimilars, Vascular Embolization Medical Devices
July 5, 2012
- AZ to Promote Symbicort, SMART Therapy Targeting GPs, Specialists
July 5, 2012
- Ono to Start PI Trial for Anticancer Vaccine Licensed from OncoTherapy
July 5, 2012
- Japan Becomes World No. 2 Vaccine Market Pushed by HPV Vaccines
July 4, 2012
- Sanofi, Hisamitsu Set Up Joint Venture with Sanofi Chief as President and Chairman
July 4, 2012
- AnGes MG to License Exclusive US Marketing Rights for Collategene to MTPC
July 4, 2012
- 230 MSs of Mediceo Begin to Work as ARs for Sawai
July 4, 2012
- COPD Treatment Oxis Approved, to Be Marketed by Meiji Seika Pharma: AZ
July 4, 2012
- Taisho Makes Tokuhon Wholly Owned Subsidiary; Expanding Business in Topical, Adhesive Agents
July 4, 2012
- Over 60% of Meiji Seika Pharma’s Generics Have Top 3 Market Share: GM Umeki
July 3, 2012
- Nippon Kayaku in Final Preparatory Stage for NK105 PIII Trials: Managing Director Suzuki
July 3, 2012
- Japan’s 5th DPP-4 Inhibitor Tenelia Approved: MTPC
July 3, 2012
- Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
July 2, 2012
- Astellas Receives Approval for Prostate Cancer Treatment Gonax
July 2, 2012
- Toyama Chemical, Eisai Receive Approval for Anti-Rheumatic Treatment, to Market under 2 Brands
July 2, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…